VTV THERAPEUT. A NEW O.N.
VTV THERAPEUT. A NEW O.N.
Acción · US9183852048 · VTVT · A3EWXG (XNCM)
Resumen Indicadores financieros
13,29 EUR
-4,06 % -0,56 EUR
Frankfurt (XNAS) · Precios actuales y gráficos en MoneyPeak
13.06.2025 19:03

Cotizaciones actuales de VTV THERAPEUT. A NEW O.N.

BolsaTickerMonedaÚltima operaciónPrecioVariación diaria
XNAS: NASDAQ
NASDAQ
VTVT
USD
13.06.2025 19:03
15,35 USD
16,00 USD
-4,06 %

Rendimiento

Día Semana Mes 3 meses 6 meses 1 año 5 años
0,57 % -6,95 % -27,46 % -2,45 % -7,16 % -32,34 % -86,35 %

Perfil de la empresa para VTV THERAPEUT. A NEW O.N. Acción

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator for renal diseases through partnerships with pharmaceutical partners. The company has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.

Datos de la empresa

Nombre VTV THERAPEUT. A NEW O.N.
Empresa vTv Therapeutics Inc.
Símbolo VTVT
Sitio web https://www.vtvtherapeutics.com
Mercado principal XNCM Frankfurt
WKN A3EWXG
ISIN US9183852048
Tipo de valor Acción
Sector Healthcare
Industria Biotechnology
CEO Mr. Paul J. Sekhri M.Sc.
Capitalización de mercado 51 Mio
País Estados Unidos de América
Moneda EUR
Empleados 0,0 T
Dirección 3980 Premier Drive, 27265 High Point
Fecha de OPV 2015-07-30

Símbolos de cotización

Nombre Símbolo
Frankfurt 5VT0.F
NASDAQ VTVT

Otras acciones

Los inversores que tienen VTV THERAPEUT. A NEW O.N. también tienen las siguientes acciones en su cartera:
DTE ELECTRIC 21/51
DTE ELECTRIC 21/51 Bono
STE GENERALE 21/27 MTN
STE GENERALE 21/27 MTN Bono
La plataforma financiera MoneyPeak rastrea y analiza inversiones y carteras. Desde depósitos de valores hasta compras de criptomonedas.
Útil, simple y gratuito. Acciones, ETF, ETC, ETN, índices, fondos, bonos, certificados, divisas, opciones, derechos de suscripción.
Aviso legal Protección de datos Blog Comunidad Comentarios Changelog
Im App Store herunterladen Bei Google Play herunterladen
Todos los derechos reservados © LCP GmbH 2025